Reynders McVeigh Capital Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.42M | Buy |
111,431
+9,658
| +9% | +$470K | 0.27% | 60 |
|
|
2025
Q1 | $3.46M | Buy |
101,773
+4,086
| +4% | +$139K | 0.19% | 63 |
|
|
2024
Q4 | $3.85M | Sell |
97,687
-21,899
| -18% | -$862K | 0.2% | 60 |
|
|
2024
Q3 | $5.62M | Buy |
119,586
+4,913
| +4% | +$231K | 0.3% | 52 |
|
|
2024
Q2 | $6.19M | Buy |
114,673
+17,694
| +18% | +$956K | 0.35% | 49 |
|
|
2024
Q1 | $6.61M | Buy |
96,979
+4,931
| +5% | +$336K | 0.38% | 50 |
|
|
2023
Q4 | $5.76M | Buy |
92,048
+15,870
| +21% | +$993K | 0.36% | 53 |
|
|
2023
Q3 | $3.46M | Buy |
76,178
+26,180
| +52% | +$1.19M | 0.24% | 57 |
|
|
2023
Q2 | $2.81M | Buy |
49,998
+31,094
| +164% | +$1.75M | 0.18% | 66 |
|
|
2023
Q1 | $855K | Buy |
+18,904
| New | +$855K | 0.06% | 96 |
|
|
2022
Q4 | – | Sell |
-3,085
| Closed | -$202K | – | 213 |
|
|
2022
Q3 | $202K | Buy |
+3,085
| New | +$202K | 0.02% | 204 |
|
|
2022
Q2 | – | Sell |
-4,680
| Closed | -$294K | – | 224 |
|
|
2022
Q1 | $294K | Buy |
4,680
+1,815
| +63% | +$114K | 0.02% | 193 |
|
|
2021
Q4 | $217K | Buy |
2,865
+165
| +6% | +$12.5K | 0.01% | 229 |
|
|
2021
Q3 | $302K | Buy |
2,700
+95
| +4% | +$10.6K | 0.02% | 190 |
|
|
2021
Q2 | $422K | Buy |
2,605
+145
| +6% | +$23.5K | 0.03% | 169 |
|
|
2021
Q1 | $300K | Buy |
2,460
+20
| +0.8% | +$2.44K | 0.02% | 195 |
|
|
2020
Q4 | $374K | Sell |
2,440
-50
| -2% | -$7.66K | 0.03% | 172 |
|
|
2020
Q3 | $208K | Buy |
+2,490
| New | +$208K | 0.02% | 213 |
|